Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Indirect hyperbilirubinemia with indinavir.

P Satija1, Falguni Parikh, V Aggarwal

  • 1Department of Medicine, TN Medical College and BYL Nair Charitable Hospital, Mumbai.

The Journal of the Association of Physicians of India
|February 6, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Freshwater Fish Biodiversity Changes Before and After the Indrapuri Dam Construction in the Bihar Region.

Integrative organismal biology (Oxford, England)·2026
Same author

Long-Range Transverse-Momentum Correlations and Radial Flow in Pb-Pb Collisions at the LHC.

Physical review letters·2026
Same author

Sex disparities and partners' positive HIV status in HIV recent infection among people who inject drugs in Ukraine.

AIDS (London, England)·2026
Same author

Impact of self-administered pulse oximetry among non-hospitalized patients at risk of severe COVID-19 in Honduras: A pragmatic, cluster-randomized trial with temporal clustering.

PLOS global public health·2025
Same author

Search for Quasiparticle Scattering in the Quark-Gluon Plasma with Jet Splittings in pp and Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2025
Same author

Bilateral Alternate Orbital and Ocular Manifestations in a VEXAS Syndrome Patient.

Ocular immunology and inflammation·2025
Same journal

Indian Expert Consensus on Allergic Rhinitis in Women: A Modified Delphi Survey.

The Journal of the Association of Physicians of India·2026
Same journal

Systematic Review of Topical Capsaicin 0.075% for the Treatment of Neuropathic Pain: Efficacy, Safety, and Tolerability.

The Journal of the Association of Physicians of India·2026
Same journal

Sodium-Glucose Cotransporter 2 Inhibitors in Kidney Diseases Other Than That Due to Diabetes: Benefits in Composite Renal Outcomes Driven by Immunoglobulin A Nephropathy.

The Journal of the Association of Physicians of India·2026
Same journal

<i>Fasciolopsis buski</i> Diagnosed by Upper Gastrointestinal Endoscopy.

The Journal of the Association of Physicians of India·2026
Same journal

"Academic Overdose" among Healthcare Professionals.

The Journal of the Association of Physicians of India·2026
Same journal

Respiratory Examination for Postgraduate Residents: Unrevealing Expert's Questions and Answers.

The Journal of the Association of Physicians of India·2026
See all related articles

Indinavir, an HIV protease inhibitor, can cause indirect hyperbilirubinemia. This adverse effect was observed in an individual receiving indinavir for post-exposure prophylaxis.

Area of Science:

  • Pharmacology
  • Toxicology
  • Infectious Diseases

Background:

  • Indinavir is a crucial protease inhibitor for HIV treatment and post-exposure prophylaxis (PEP).
  • Known adverse effects include gastrointestinal issues, lipodystrophy, and nephrolithiasis.
  • The full spectrum of indinavir's side effects requires ongoing investigation.

Observation:

  • A case study documented an individual undergoing PEP with indinavir.
  • This individual presented with indirect hyperbilirubinemia.
  • This specific adverse effect has not been widely reported for indinavir.

Findings:

  • Indirect hyperbilirubinemia emerged as an adverse effect of indinavir therapy.
  • This finding suggests a potential impact on bilirubin metabolism.

Related Experiment Videos

  • The association was noted in the context of PEP.

    • Implications:

    • Clinicians should be aware of indirect hyperbilirubinemia as a potential indinavir side effect.
    • Monitoring bilirubin levels may be warranted in patients receiving indinavir, especially for PEP.
    • Further research is needed to elucidate the mechanism and prevalence of this adverse event.